Horizon Therapeutics Public Limited (HZNP) Return on Assets ROA from the second quarter of 2023 to second quarter of 2022 and for the year 2023, Average High and Low, Fundamental Ratios from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Horizon Therapeutics Public Limited Company  (NASDAQ: HZNP)


Horizon Therapeutics Public Limited's ROA from the second quarter of 2023 to the second quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Horizon Therapeutics Public Limited's ROA in the second quarter of 2023?
Horizon Therapeutics Public Limited Company achieved a return on average assets (ROA) of 4.81 % in its second quarter of 2023, this is above HZNP's average return on assets of -17.06%.
Horizon Therapeutics Public Limited Companys assets during the 12 months ending in the second quarter of 2023 are valued at $9 billion

ROA has improved compared to 4.13% in the first quarter of 2023, due to net income growth.

However, within the Healthcare sector 134 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2023 quarter, so far to 1313, from total ROA ranking in the first quarter of 2023 at 1489.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Total Assets Change 5.03 % 2.9 % 5.03 % 4.87 % 7.87 %
Y / Y Net Income Change 108.4 % -73.23 % -30.47 % -58.4 % -61.44 %
Net Income (TTM) in million 438 372 521 574 765
Return On Assets (TTM) 4.81 % 4.13 % 5.84 % 6.51 % 8.77 %
HZNP's Total Ranking # 1313 # 1489 # 1434 # 1191 # 944
Total Assets (TTM) in million 9,299 8,993 9,115 9,028 8,853
Seq. Total Assets Change 3.39 % -1.33 % 0.96 % 1.97 % 1.29 %
Seq. Net Income Change 132.37 % -54.58 % -11.36 % 122.78 % -70.15 %

HZNP's 5 Years Annual ROA >> Back to HZNP Management Effectiveness >> Compare HZNP ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 54
Sector # 135
Overall # 1295

Return On Assets Statistics
High Average Low
16.63 %
-17.06 %
-153.41 %
(Sep 30 2020)   (Mar 31 2014)





Financial Statements
Horizon Therapeutics Public Limited's Assets $ 9,299 million HZNP's Balance sheet
Horizon Therapeutics Public Limited's Income $ 127 million Quarterly HZNP's Income Statement
HZNP's Income by Division See HZNP's Income by Division



Annual Return On Assets (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
Y / Y Total Assets Change 5.03 % 42.9 % 36.89 % 6.99 % -0.47 %
Total Assets in million 9,115 8,678 6,073 4,436 4,146
Y / Y Net Income Change -2.43 % 37.12 % -31.98 % - -
Net Income in million 521 534 390 573 -74
Annual Return On Assets 5.72 % 6.16 % 6.42 % 12.92 % -1.79 %

HZNP's 5 Years Annual ROA >> Back to HZNP Management Effectiveness >> Compare HZNP ROA to its Competitors



Comment on HZNP's ROA in the fiscal year ending 2022
In the fiscal year 2022 Horizon Therapeutics Public Limited's ROA decreased compared to previous year to 5.72 %, due to deterioration of net income -2.43 % to $521.48 million, from $534.49 million a year ago, as HZNP's assets were $9,114.62 million.


More Return On Assets Ratios
HZNP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HZNP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HZNP's Competitors
Subscribers only: Roa for Horizon Therapeutics Public Limited's Suppliers
Subscribers only: Return On Assets for HZNP's Customers

You may also want to know
HZNP's Roi HZNP's Inventory Turnover Ratio HZNP's Growth Rates HZNP's Dividend Comparisons
HZNP's Profitability Ratios HZNP's Asset Turnover Ratio HZNP's Dividend Growth
HZNP's Roe HZNP's Valuation Ratios HZNP's Financial Strength Ratios HZNP's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2023, within Healthcare Sector ROA
Hca Healthcare Inc   13.21 %
Exicure Inc   13.07 %
Halozyme Therapeutics Inc   12.95 %
Ufp Technologies Inc   12.76 %
Eli Lilly And Company  12.68 %
Exelixis Inc   12.13 %
Bio techne Corp  11.55 %
Dynavax Technologies Corporation  11.34 %
Amphastar Pharmaceuticals Inc   11.26 %
Intuitive Surgical Inc   10.89 %
Biogen Inc   10.75 %
Agilent Technologies inc   10.66 %
Pfizer Inc  10.65 %
Sep Acquisition Corp   10.53 %
Amgen Inc   10.37 %
Alpha Pro Tech Ltd   10.18 %
Elite Pharmaceuticals Inc   10.17 %
Carlisle Companies Incorporated  9.92 %
Globus Medical Inc   9.71 %
Orasure Technologies Inc  9.67 %
Precigen Inc   9.59 %
Escalon Medical Corp   8.90 %
Bruker Corporation  8.84 %
Schrodinger Inc   8.76 %
Cv Sciences Inc   8.72 %
Gilead Sciences Inc   8.71 %
Thorne Healthtech Inc   8.38 %
Bristol myers Squibb Company  8.34 %
Progyny Inc   8.27 %
Lemaitre Vascular Inc   8.05 %

Date modified: 2026-09-12T06:14:33+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.